Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients
Lin, P.-H.; Chen, S.-C.; Tseng, L.-M.; Chang, K.-J.; Huang, A.-C.; Cheng, K.-C.; Yang, K.; Wu, H.-C.; Chao, T.-Y.; Chang, Y.-C.; Lin, P.-C.; Kuo, W.-H.; Kuo, W.-L.; Lin, C.-H.; Chen, H.-M.; Yeh, D.-C.; Liu, L.-C.; Liu, C.-Y.; Wang, M.-Y.; Lo, C.; Lu, Y.-S.; Huang, C.-S.
Breast Cancer Research and Treatment 192(3): 629-637
ISSN/ISBN: 1573-7217 PMID: 35113257 Accession: 079644485
Breast cancer is increasing around the globe, including Asia. We aimed to examine the survival and risk of contralateral breast cancer (CBC) in Asian breast cancer patients with BRCA mutations. A total of 128 breast cancer patients with germline BRCA mutations and 4,754 control breast cancer patients were enrolled. Data on clinical-pathologic characteristics, survival, and CBC were collected from the medical record. The rates of survival and CBC were estimated by Kaplan-Meier method. The mean age of onset in BRCA mutation carriers was significantly younger than control patients (BRCA vs. Non-BRCA: 43.9 vs. 53.2 years old). BRCA mutation carriers had a higher proportion of triple-negative breast cancer (TNBC) (52%) than control patients (12%, p < 0.001). The risk of CBC was significantly higher in BRCA mutation patients than in control cases (hazard ratio (HR) = 3.95, 95% CI 2.71-5.75); when stratified by genotype, the HRs (95%CI) were 4.84 (3.00-7.82) for BRCA1 and 3.13 (1.78-5.49) for BRCA2 carriers, respectively. Moreover, BRCA1 mutation patients with triple-negative breast cancer (TNBC) as their first breast cancer had the highest risk of CBC (HR = 5.55, 95% CI 3.29-9.34). However, we did not observe any differences in relapse-free survival and overall survival between mutation carriers and control patients. Our study suggest that BRCA patients had a significantly higher risk of developing CBC, particularly for BRCA1 mutation carriers with TNBC as the first breast cancer.